PMID- 11129426
OWN - NLM
STAT- MEDLINE
DCOM- 20010208
LR  - 20191210
IS  - 1068-9265 (Print)
IS  - 1068-9265 (Linking)
VI  - 7
IP  - 10
DP  - 2000 Dec
TI  - Dendritic cells armed with anti-CD3 mAbs reduce pulmonary metastases, prolong 
      survival, and engender antitumor effector cells demonstrable by adoptive 
      transfer.
PG  - 771-6
AB  - BACKGROUND: Dendritic cells (DCs) pulsed with tumor cells or peptides are 
      effective antitumor agents in a number of tumor models. In light of our earlier 
      demonstration that T-cell signaling via the CD3 proteins induces cytolytic 
      activity and constrains tumor progression, we equipped DCs pulsed with tumor 
      cells with anti-CD3 mAbs and tested their antitumor efficacy in a murine renal 
      cell cancer pulmonary metastasis model. METHODS: We investigated the antitumor 
      efficacy of DCs pulsed with whole irradiated tumor cells (DC/R) or DCs pulsed 
      with irradiated tumor cells and armed with anti-CD3 mAbs (DC/R/anti-CD3 mAbs). 
      Experimental end points included the number of pulmonary metastases and survival 
      of tumor-inoculated mice. RESULTS: Our studies demonstrate that arming 
      tumor-pulsed DCs with anti-CD3 mAbs results in a superior outcome compared to 
      that from tumor-pulsed DCs alone in terms of reduction in the number of pulmonary 
      metastases and survival times. Furthermore, adoptive transfer experiments 
      revealed that the splenocytes from DC/R/anti-CD3 mAbs-treated mice are superior 
      to splenocytes from DC/R-treated mice in reducing renal cancer pulmonary 
      metastases in severe combined immunodeficient (SCID) beige mice. CONCLUSION: Our 
      data suggest that the therapeutic efficacy of DCs pulsed with tumor cells can be 
      augmented by arming them with anti-CD3 mAbs. DC-based treatment regimens that 
      currently are being pursued in clinical trials might be improved by equipping 
      such cells with anti-CD3 mAbs.
FAU - Maluccio, M A
AU  - Maluccio MA
AD  - Department of Surgery, New York Presbyterian Hospital/Weill Medical College of 
      Cornell University, New York 10021, USA.
FAU - Rao, J
AU  - Rao J
FAU - Sharma, V
AU  - Sharma V
FAU - Lagman, M
AU  - Lagman M
FAU - Suthanthiran, M
AU  - Suthanthiran M
LA  - eng
GR  - CA75732/CA/NCI NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD3 Complex)
SB  - IM
MH  - Adoptive Transfer
MH  - Animals
MH  - Antibodies, Monoclonal
MH  - *CD3 Complex
MH  - Carcinoma, Renal Cell/immunology/*secondary/*therapy
MH  - *Dendritic Cells
MH  - *Immunotherapy, Adoptive
MH  - Kidney Neoplasms/pathology
MH  - Lung Neoplasms/*secondary/*therapy
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, SCID
MH  - Models, Animal
MH  - Survival Analysis
EDAT- 2000/12/29 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/12/29 11:00
PHST- 2000/12/29 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/12/29 11:00 [entrez]
AID - 10.1007/s10434-000-0771-9 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2000 Dec;7(10):771-6. doi: 10.1007/s10434-000-0771-9.